Chongqing Pharscin Pharmaceutical Co Ltd (002907) - Total Liabilities
Based on the latest financial reports, Chongqing Pharscin Pharmaceutical Co Ltd (002907) has total liabilities worth CN¥287.66 Million CNY (≈ $42.09 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 002907 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Chongqing Pharscin Pharmaceutical Co Ltd - Total Liabilities Trend (2013–2024)
This chart illustrates how Chongqing Pharscin Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 002907 total assets.
Chongqing Pharscin Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Chongqing Pharscin Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sinoseal Holding Co Ltd
SHE:300470
|
China | CN¥511.52 Million |
|
TrustCo Bank Corp NY
NASDAQ:TRST
|
USA | $5.84 Billion |
|
Core Lithium Ltd
AU:CXO
|
Australia | AU$20.49 Million |
|
Shenzhen Tianyuan Dic Info Tech
SHE:300047
|
China | CN¥4.04 Billion |
|
Flowco Holdings Inc.
NYSE:FLOC
|
USA | $553.99 Million |
|
Nesco Limited
NSE:NESCO
|
India | Rs-29.96 Billion |
|
Shenzhen Tellus Holding Co Ltd
SHE:000025
|
China | CN¥677.71 Million |
|
Darma Henwa Tbk
JK:DEWA
|
Indonesia | Rp50.36 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Chongqing Pharscin Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Chongqing Pharscin Pharmaceutical Co Ltd (002907) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chongqing Pharscin Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chongqing Pharscin Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual total liabilities of Chongqing Pharscin Pharmaceutical Co Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥257.55 Million ≈ $37.69 Million |
+10.28% |
| 2023-12-31 | CN¥233.53 Million ≈ $34.17 Million |
-8.87% |
| 2022-12-31 | CN¥256.28 Million ≈ $37.50 Million |
-49.31% |
| 2021-12-31 | CN¥505.56 Million ≈ $73.98 Million |
-6.31% |
| 2020-12-31 | CN¥539.59 Million ≈ $78.96 Million |
-4.78% |
| 2019-12-31 | CN¥566.67 Million ≈ $82.92 Million |
+114.07% |
| 2018-12-31 | CN¥264.72 Million ≈ $38.74 Million |
+60.24% |
| 2017-12-31 | CN¥165.20 Million ≈ $24.17 Million |
-13.47% |
| 2016-12-31 | CN¥190.91 Million ≈ $27.94 Million |
+9.98% |
| 2015-12-31 | CN¥173.59 Million ≈ $25.40 Million |
-26.95% |
| 2014-12-31 | CN¥237.62 Million ≈ $34.77 Million |
+36.26% |
| 2013-12-31 | CN¥174.39 Million ≈ $25.52 Million |
-- |
About Chongqing Pharscin Pharmaceutical Co Ltd
Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs in China. The company offers tablets, powders, granules, soft capsules, powder injections, freeze-dried powders, injections, chemical raw materials, and small volume injections. It provides its products for the treatment of CNS, digestion, otolaryngology, oncology, cardiovascular, an… Read more